ClinicalTrials.gg
CompletedNCT04484935MUSICUpdated Nov 15, 2023Results posted

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

A Phase 2 interventional study of Nirsevimab in RSV Infection, sponsored by AstraZeneca. Completed at 28 sites in 8 countries. Open to participants aged 0 Years to 2 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
0 Years to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca — none open to participants now, none under way, none of them phase 3. Respiratory Syncytial Virus Infections · AstraZeneca.

Enrollment
8th of 12
100 · median 239
Started
2020
the only one that year
Phase 2
3 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 2, and was the 13th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Respiratory Syncytial Virus Infections by AstraZeneca as a file.
02

Study summary

Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised children who are ≤ 24 months of age at the time of dose administration. Approximately 100 subjects will be enrolled. Subjects will be followed for approximately 1 year after dose administration.

Read the detailed description

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) among infants and young children, resulting in annual epidemics in Japan. Children with congenital or acquired immunodeficiencies, transplant recipients, and those receiving immunosuppressive therapy are at increased risk for severe RSV-associated LRTI with prolonged viral shedding and higher viral loads, resulting in prolonged hospitalizations, admissions to the intensive care unit (ICU), and the need for mechanical ventilation. Palivizumab (Synagis®) is the only approved agent for RSV prophylaxis, and its half-life (t1/2) is approximately 1 month, infants and young children need to receive monthly intramuscular doses of palivizumab throughout the RSV season to maintain protection. This constitutes a significant burden on healthcare providers as well as the infants/children and their families.

Nirsevimab may provide a cost-effective opportunity to protect all infants from RSV disease based on an improvement in potency and the extended t1/2 that is expected to support once-per-RSV-season dosing.

03

Conditions studied

  • RSV Infection

Keywords

  • LRTI by RSV infection
04

Who can participate

Ages eligible
0 Years to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonate, infant, or young child ≤ 24 months of age at the time of dose administration who, per investigator judgement, are:

    1. In their first year of life AND entering their first RSV season at the time of dose administration OR
    2. In their second year of life AND entering their second RSV season at the time of dose administration
  • The subject must meet at least 1 of the following conditions at the time of .

    1. Diagnosed with combined immunodeficiency (severe combined immunodeficiency, X-linked hyper-immunoglobulin M [IgM] syndrome, etc); antibody deficiency (X linked agammaglobulinemia, common variable immunodeficiency, non-X-linked hyper-IgM syndromes, etc); or other immunodeficiency (Wiskott-Aldrich syndrome, DiGeorge syndrome, etc), or
    2. Diagnosed with infection, or
    3. History of organ or bone marrow transplantation, or
    4. Subject is receiving chemotherapy, or
    5. Subject is receiving systemic high-dose therapy (prednisone equivalents ≥ 0.5 mg/kg every other day, other than inhaler or topical use), or
    6. Subject is receiving other immunosuppressive therapy (eg, azathioprine, methotrexate, mizoribine, mycophenolate mofetil, cyclophosphamide, cyclosporine, tacrolimus, cytokine inhibitors, etc)
  • Written informed consent and any locally required authorization obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations.
  • Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up visits as judged by the investigator.
  • Subject is available to complete the follow-up period, which will be approximately 1 year after receipt of nirsevimab

Exclusion criteria

Exclusion Criteria:

  • Subject who meets any of the palivizumab indications approved in Japan other than condition.

    1. Subject born at ≤ 28 weeks gestation and is ≤ 12 months of age
    2. Subject born at 29 to 35 weeks gestation and is ≤ 6 months of age
    3. Age ≤ 24 months with a history of bronchopulmonary dysplasia requiring medical management within the past 6 months
    4. Age ≤ 24 months with current hemodynamically significant congenital heart disease (CHD)
    5. Age ≤ 24 months with Down syndrome
  • Requirement for oxygen supplementation, mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, or other mechanical respiratory or cardiac support at screening
  • A current, active infection, including RSV infection, at the time of screening or at the time of product administration.
  • Any fever (≥ 100.4°F [≥ 38.0°C], regardless of route) or acute illness within 7 days prior to investigational product administration.
  • Any serious concurrent medical condition (renal failure, hepatic dysfunction, suspected active or chronic hepatitis infection, seizure disorder, unstable neurologic disorder, etc), except those resulting in an immune deficiency condition.
  • congenital anomaly of the respiratory tract.
  • Receipt of palivizumab.
  • Any known allergy or history of allergic reaction to any component of nirsevimab.
  • Any known allergy or history of allergic reaction to immunoglobulin products, blood products, or other foreign proteins.
  • Concurrent enrollment in another interventional study, or prior receipt of any investigational agent.
  • Anticipated survival of less than 1 year at the time of .
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of study results.
  • Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Nirsevimab

    1st RSV season: 50mg nirsevimab 1. st RSV season: 100mg nirsevimab 2. nd RSV season: 200mg nirsevimab

    Drug: Nirsevimab

Interventions

  • Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg

    Also known as: Nirsevimab (MEDI8897)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic Disease (NOCDs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab and within 360 days post dose. A TESAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant. AESIs were defined as AEs of immediate (type I) hypersensitivity (including anaphylaxis), thrombocytopenia, and immune complex disease following the administration of nirsevimab based on investigator assessment and Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) codes. An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature post administration of treatment.

    Time frame: TEAEs were collected from the first dose administration (Day 1) up to 360 days post dose

Secondary outcomes

  1. Serum Concentrations of Nirsevimab

    Serum concentrations of nirsevimab at selected time points were evaluated to confirm that adequate exposures for protection from respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) are maintained for at least 5 months after dosing.

    Time frame: Baseline (Day 1) and on Days 8 (for Japanese participants), 31, 151 and 361

  2. Number of Participants With Anti-Drug Antibody (ADA) Response to Nirsevimab

    Blood samples were analyzed for the presence of ADAs for nirsevimab using validated assays.

    Time frame: Baseline (Day 1) and on Days 31, 151 and 361

  3. Number of Participants With Medically Attended (MA) RSV LRTI (Inpatient and Outpatient) and Hospitalizations

    Number of participants with LRTI and hospitalizations due to reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed RSV was assessed. MA RSV LRTI consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient or outpatient setting. MA RSV LRTI with hospitalization consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient setting.

    Time frame: Through 150 days post dose

07

Results

Posted Nov 15, 2023

Participant flow

This Phase 2, open-label, uncontrolled, single-dose study was conducted at 28 investigational sites in 8 countries (Belgium, Japan, Poland, South Africa, Spain, Ukraine, United Kingdom and United States) in immunocompromised children who were \<=24 months of age at the time of enrollment between 19 Aug 2020 and 17 Feb 2023.

Participant flow — Overall Study
MilestoneNirsevimab 50 mg/100 mgNirsevimab 200 mg
Started4852
Completed4549
Not completed33
Withdrew: Other01
Withdrew: Withdrawal by parent/guardian01
Withdrew: Lost to follow-up10
Withdrew: Death21

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic Disease (NOCDs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the treatment. TEAEs were AEs whose onset occurred after receiving nirsevimab and within 360 days post dose. A TESAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality, or was medically significant. AESIs were defined as AEs of immediate (type I) hypersensitivity (including anaphylaxis), thrombocytopenia, and immune complex disease following the administration of nirsevimab based on investigator assessment and Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) codes. An NOCD was a newly diagnosed medical condition of a chronic, ongoing nature post administration of treatment.

Time frame:
TEAEs were collected from the first dose administration (Day 1) up to 360 days post dose
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs (TESAEs), AEs of Special Interest (AESIs), and New Onset Chronic Disease (NOCDs)
ParticipantsNirsevimab 50 mg/100 mgNirsevimab 200 mg
Any TEAE3645
TESAE1220
AESI based on investigator assessment32
AESI based on selected MedDRA PT codes1613
NOCD00
SecondarySerum Concentrations of Nirsevimab

Serum concentrations of nirsevimab at selected time points were evaluated to confirm that adequate exposures for protection from respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) are maintained for at least 5 months after dosing.

Time frame:
Baseline (Day 1) and on Days 8 (for Japanese participants), 31, 151 and 361
Reported as:
Geometric mean · mcg/mL
Serum Concentrations of Nirsevimab
mcg/mLNirsevimab 50 mg/100 mgNirsevimab 200 mg
Baseline (Day 1)NA ± NANA ± NA
Day 8139.24 ± 22.26206.79 ± 16.58
Day 3166.00 ± 141.06109.77 ± 91.74
Day 15119.80 ± 101.1924.14 ± 121.54
Day 3611.86 ± 119.961.93 ± 158.95
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Nirsevimab

Blood samples were analyzed for the presence of ADAs for nirsevimab using validated assays.

Time frame:
Baseline (Day 1) and on Days 31, 151 and 361
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Nirsevimab
ParticipantsNirsevimab 50 mg/100 mgNirsevimab 200 mg
Day 100
Day 3101
Day 15110
Day 36127
SecondaryNumber of Participants With Medically Attended (MA) RSV LRTI (Inpatient and Outpatient) and Hospitalizations

Number of participants with LRTI and hospitalizations due to reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed RSV was assessed. MA RSV LRTI consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient or outpatient setting. MA RSV LRTI with hospitalization consisted of participants with protocol-defined LRTI, positive central RT-PCR RSV test result, Investigator assessed LRTI at an inpatient setting.

Time frame:
Through 150 days post dose
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended (MA) RSV LRTI (Inpatient and Outpatient) and Hospitalizations
ParticipantsNirsevimab 50 mg/100 mgNirsevimab 200 mg
MA RSV LRTI00
MA RSV LRTI with hospitalization00

Adverse events

Collected over The TEAEs were collected from the first dose administration (Day 1) up to 360 days post dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nirsevimab 50 mg/100 mg2/48 (4.2%)12/48 (25%)35/48 (72.9%)
Nirsevimab 200 mg1/52 (1.9%)20/52 (38.5%)41/52 (78.8%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventNirsevimab 50 mg/100 mgNirsevimab 200 mg
PneumoniaInfections and infestations1/484/52
Lower respiratory tract infectionInfections and infestations1/483/52
COVID-19Infections and infestations1/483/52
Rhinovirus infectionInfections and infestations2/480/52
Viral diarrhoeaInfections and infestations2/480/52
PyrexiaGeneral disorders2/481/52
Candida sepsisInfections and infestations2/480/52
Klebsiella sepsisInfections and infestations0/482/52
ThrombocytopeniaBlood and lymphatic system disorders0/482/52
Nephrotic syndromeRenal and urinary disorders0/482/52
Most frequent other events
Showing 10 of 30
Most frequent other events
EventNirsevimab 50 mg/100 mgNirsevimab 200 mg
Upper respiratory tract infectionInfections and infestations18/4818/52
PyrexiaGeneral disorders13/4813/52
VomitingGastrointestinal disorders8/4813/52
COVID-19Infections and infestations4/4812/52
DiarrhoeaGastrointestinal disorders8/4810/52
Dermatitis diaperSkin and subcutaneous tissue disorders5/488/52
RhinorrhoeaRespiratory, thoracic and mediastinal disorders6/487/52
NasopharyngitisInfections and infestations6/486/52
CoughRespiratory, thoracic and mediastinal disorders6/484/52
Otitis mediaInfections and infestations5/486/52

Baseline characteristics

The As-treated population consisted of all participants who were enrolled and received any dose of nirsevimab.

Age, Continuous
Age, Continuous(months)Nirsevimab 50 mg/100 mgNirsevimab 200 mgTotal
Mean7.64 ± 3.27017.90 ± 3.74812.97 ± 6.232
Sex: Female, Male
Sex: Female, Male(Participants)Nirsevimab 50 mg/100 mgNirsevimab 200 mgTotal
Female181735
Male303565
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nirsevimab 50 mg/100 mgNirsevimab 200 mgTotal
Hispanic or Latino437
Not Hispanic or Latino444993
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nirsevimab 50 mg/100 mgNirsevimab 200 mgTotal
Asian161228
American Indian or Alaskan Native101
Black or African American91120
Native Hawaiian or Other Pacific Islander000
White202545
Other224
Multiple categories checked022
08

Study locations

28 sites
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Memphis, Tennessee 38105, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Bunkyo-ku, 113-8519, Japan
  • Research Site
    Fuchu-shi, 183-8561, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Kyoto-shi, 606-8507, Japan
  • Research Site
    Nagasaki-shi, 852-8501, Japan
  • Research Site
    Setagaya-ku, 157-8535, Japan
  • Research Site
    Tsukuba-shi, 305-8576, Japan
  • Research Site
    Yokohama-shi, 232 8555, Japan
  • Research Site
    Bydgoszcz, 85-048, Poland
  • Research Site
    Parktown, 2193, South Africa
  • Research Site
    Soweto, 2013, South Africa
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Dnipro, 49006, Ukraine
  • Research Site
    Kharkiv, 61075, Ukraine
  • Research Site
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AstraZeneca (AZ) disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AstraZeneca (AZ) are accepting requests for Individual Participant Data (IPD), but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Feb 2023, 29 months.

Results were first posted in Nov 2023, 8 months after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 29 months is above that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 24, 2020
StartActual
Aug 19, 2020
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 17, 2023
Results first posted
Nov 15, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04484935
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Jul 24, 2020
Start date
Aug 19, 2020
Primary completion
Feb 17, 2023
Completion
Feb 17, 2023
Results posted
Nov 15, 2023
Last update
Nov 15, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion